Lucid-MS Moves to Phase 2 After Successful Phase 1 Safety Trials
QNTM•Quantum BioPharma’s patented Lucid-MS has completed Phase 1 safety and tolerability studies and is moving into Phase 2 trials as a non-immunomodulatory neuroprotective therapy for multiple sclerosis. The company is collaborating with Massachusetts General Hospital to validate a novel PET imaging technique for direct measurement of myelin integrity.
1. Lucid-MS Advances to Phase 2 Trials
Quantum BioPharma’s lead drug candidate Lucid-MS, a patented first-in-class neuroprotective therapy for multiple sclerosis, completed Phase 1 safety and tolerability studies and is now entering Phase 2 clinical trials.
2. Preclinical Efficacy and Research Backing
Lucid-MS has shown the ability to prevent and reverse myelin degradation in preclinical models, supported by over a decade of scientific research, distinguishing it from conventional immunomodulatory MS treatments.
3. Collaboration on Myelin Imaging
The company is partnering with Massachusetts General Hospital to validate a novel PET imaging technique aimed at directly measuring myelin integrity in MS patients, potentially enhancing clinical assessment capabilities.
